Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440)

British Journal of Cancer

Volumn 76, Issue 7, 1997, Pages 862-869

  Hofmann, J ^a   Utz, I ^a   Spitaler, M ^a   Hofer, S ^a   Rybczynska, M ^a   Beck, W T ^b   Herrmann, D B J ^c   Grunicke, H ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

BM 41 440; Ilmofosine; MDR1; MDR2; Multidrug resistance

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); GLYCOPROTEIN P; ILMOFOSINE; MESSENGER RNA;

ARTICLE; CELL LINE; CLINICAL TRIAL; HELA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030777237     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.476     Document Type: Article

References (33)

1. Ahmad S and Glazer RI (1993) Expression of the antisense cDNA for protein kinase Cα attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol 43: 858-862
2. Beck WT, Mueller TJ and Tanzer LR (1979) Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39: 2070-2076
3. Berdel WE (1991) Membrane-interactive lipids as experimental anticancer drugs. Br J Cancer 64: 208-211
4. Chambers TC, Zheng B and Kuo JF (1992) Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol Pharmacol 41: 1008-1015
5. Chaudhary PM and Roninson IB (1992) Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol Res 4: 281-290
6. Danks MK, Schmidt CA, Cirtain MC, Shuttle DP and Beck WT (1988) Altered catalytic activity of and DNA cleavage by topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861-8869
7. Doige CA, Yu X and Sharom FF (1992) ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochim Biophys Acta 1109: 149-160
8. Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171
9. Fleer EAM, Berkovic D, Eibl H and Unger C (1993) Investigations on the cellular uptake of hexadecylphosphocholine. Lipids 28: 731-736
10. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance by the multidrug transporter. Annu Rev Biochem 62: 385-427
11. Hamada H and Tsuruo T (1988) Purification of 170-180 kilodalton membrane P-glycoprotein associated with multidrug resistance. J Biol Chem 263: 1454-1458
12. Herrmann DBJ (1985) Changes in cellular lipid synthesis of normal and neoplastic cells during cytolysis induced by alkyl lysophospholipid analogues. J Natl Cancer Inst 75: 423-430
13. Himmelmann AW, Dannhauser-Riedl S, Steinhauser G, Busch R, Modest EJ, Noseda A, Rastetter J, Vogler RW and Berdel WE (1990) Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro. Cancer Chemother Pharmacol 26: 437-443
14. Hofmann J, Ueberall F, Posch L, Maly K, Hermann DBJ and Grunicke H (1989) Synergistic enhancement of the antiproliferative activity of cis-diamminedichloro-platinuml(II) by the ether lipid analogue HM41440, an inhibitor of protein kinase C. Lipids 24: 312-317
15. Hofmann J, Wolf A, Spitaler M, Böck G, Drach J, Ludescher C and Grunicke H (1992) Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J Cancer Res Clin Oncol 118: 381-366
16. Hofmann J, O'Connor PM, Jackman J, Schubert C, Ueberall F, Kohn KW and Grunicke H (1994) The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents. Biochem Biophys Res Commun 199: 937-943
17. Kane SE, Reinhard DH, Fordis MC, Pastan I and Gottesman MM (1989) A new vector using the human multidrug resistance gene as a selectible marker enables overexpression of foreign genes into eukaryotic cells. Gene 84: 439-446
18. Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, Diddens H and Niethammer D (1990) Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 50: 6793-6799
19. Lavie Y, Ca H, Bursten SL, Armando GE and Cabot MC (1996) Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 271: 19530-19536
20. Le Moyec L, Tatoud R, Degeorges A, Calabresse C, Bauza G, Euene M and Calvo F (1996) Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adramycin and taxol by the K562 leukemia cell line. Cancer Res 56: 3461-3467
21. Ma L, Marquart D, Takemoto L and Center MS (1991) Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. J Biol Chem 266: 5593-5599
22. Metherall JE, Li H and Waugh K (1996) Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis. J Biol Chem 271: 2634-2640
23. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD and Roninson IB (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87: 7160-7164
24. Petersen ES, Kelley EE, Modest EJ and Burns PC (1992) Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440. Cancer Res 52: 6263-6269
25. Powis G, Seewald MJ, Gratas C, Melder D, Riebow J and Modest EJ (1992) Selective inhibition of phosphatidylinositol phospholipase-C by cytotoxic ether lipid analogs. Cancer Res 52: 2835-2840
26. Principe P, Coulomb H, Broquet C and Braquet P (1992) Evaluation of combinations of antineoplastic ether lipids and chemotherapeutic drugs. Anti-Cancer Drugs 3: 577-587
27. Principe P, Fausat-Suberville AM, Coulomb H, Marie J-P and Braquet P (1994) Flow cytometric monitoring of anthracycline accumulation after anti-neoplastic ether phospholipid treatment. Anti-Cancer Drugs 5: 329-335
28. Ruetz S and Gros P (1994) Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77: 1071-1081
29. Sampson E, Wolff C and Abraham I (1993) Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Lett 68: 7-14
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotovicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
31. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, Van Deemter L, Mol Caam, Ottenhoff R, Van Der Lugt NMT, Van Roon MA, Van Der Valk MA, Offerhaus GJA, Berns AJM and Porst P (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile to liver disease. Cell 75: 451-462
32. Thorgeirsson SS, Silverman JA, Gant TW and Marino PA (1991) Multidrug resistance gene family and chemical carcinogenesis. Pharmaceut Ther 49: 283-292.
33. Winkelmann M, Ebeling K, Strohmeyer G, Hottenrott G, Mechl Z, Berges W, Scholten T, Westerhausen M, Schlimok G and Sterz R (1992) Treatment results of the thioether lipid ilmofosine in patients with malignant tumours. J Cancer Res Clin Oncol 118: 405-407